Decreased circulating lipoprotein-associated phospholipase A2 levels are associated with coronary plaque regression in patients with acute coronary syndrome.

[1]  J. Lekakis,et al.  The role of lipoprotein-associated phospholipase A2 (Lp-PLA₂) in cardiovascular disease. , 2011, Reviews on recent clinical trials.

[2]  T. Kurata,et al.  Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study. , 2010, Atherosclerosis.

[3]  Takafumi Hiro,et al.  Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). , 2009, Circulation journal : official journal of the Japanese Circulation Society.

[4]  P. McCullough.  Darapladib and atherosclerotic plaque: Should lipoprotein-associated phospholipase A2 be a therapeutic target? , 2009, Current atherosclerosis reports.

[5]  Katsumi Miyauchi,et al.  Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin , 2009, Journal of the American College of Cardiology.

[6]  Ping Zhang,et al.  Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development , 2008, Nature Medicine.

[7]  Frits Mastik,et al.  Effects of the Direct Lipoprotein-Associated Phospholipase A2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque , 2008, Circulation.

[8]  Jeffrey L. Anderson,et al.  Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. , 2008, The American journal of cardiology.

[9]  S. Solomon,et al.  Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Elm,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[11]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Annals of Internal Medicine [serial online].

[12]  F. Kronenberg,et al.  Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes: Prospective Results From the Bruneck Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Paul Schoenhagen,et al.  Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. , 2007, JAMA.

[14]  Edward A Dennis,et al.  The phospholipase A2 superfamily and its group numbering system. , 2006, Biochimica et biophysica acta.

[15]  R. Virmani,et al.  Lipoprotein-Associated Phospholipase A2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Raimund Erbel,et al.  Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. , 2006, JAMA.

[17]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[18]  A. Zalewski,et al.  ATVB in Focus Novel Approaches to the Treatment of Dyslipidemia , 2005 .

[19]  K. Sudhir.  Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. , 2005, The Journal of clinical endocrinology and metabolism.

[20]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[21]  Paul Schoenhagen,et al.  Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.

[22]  A. Tselepis,et al.  Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. , 2002, Atherosclerosis. Supplements.

[23]  Makoto Murakami,et al.  Phospholipase A2 enzymes. , 2002, Prostaglandins & other lipid mediators.

[24]  H. Krumholz.  Lipoprotein-Associated Phospholipase A , 2001 .

[25]  M. Toyosato,et al.  Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[26]  T. Häkkinen,et al.  Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[27]  D. Tew,et al.  Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. , 1999, The Biochemical journal.

[28]  Jonathan E. Dickerson,et al.  Supplementary webappendix , 2013 .